| 1 |
35448150 | Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study. | 2022 Mar 22 |
1 |
| 2 |
33159967 | A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition. | 2021 Jan |
1 |
| 3 |
33777941 | Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. | 2021 |
2 |
| 4 |
31375978 | Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer - the role of STAT3 and p21. | 2020 Aug |
5 |
| 5 |
30381447 | Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017. | 2019 Feb |
1 |
| 6 |
28830912 | Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. | 2018 Oct |
3 |
| 7 |
27256378 | Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. | 2016 Sep |
7 |
| 8 |
27678331 | Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth. | 2016 Dec |
4 |
| 9 |
25081321 | Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. | 2014 Dec |
8 |